Acute pancreatitis (AP), characterized by complex complications, substantial treatment expenses, and elevated mortality rates in severe instances involving multi-organ dysfunction and post-recovery challenges, has traditionally been addressed through Traditional Chinese Medicine (TCM) based on the “Hot Disease” theory. Recent research, however, indicates potential adverse effects from over-relying on this approach with bitter and cold purgative herbals. Evolving from this, a novel methodology, conceptualized by Professor ZHANG Zailiang, integrates the theory of typhoid fever, miscellaneous diseases and epidemic febrile diseases. This paradigm shift encompasses the entire AP spectrum, emphasizing early interventions for organ damage, proactive complication management, and meticulous post-recovery care. It proposes a comprehensive, tailored strategy for monitoring disease evolution and convalescence, signaling a significant advancement in the AP treatment paradigm, particularly in the context of TCM’s role in critical care.
目的:探討早期采用益活清下法治療重癥急性胰腺炎(severe acute pancreatitis,SAP)并腎功能不全的療效。方法:35 例符合病例選擇標準并接受益活清下法治療的SAP并發腎功能不全患者,按發病后入院時間分為早期組(3d 內入院接受治療,24例)和晚期組(3～7 d 內入院接受治療,11例),比較治療過程中兩組患者各并發癥的持續時間、病程、手術中轉率及病死率。結果:兩組入院48小時Ranson 評分、急性生理和慢性健康評價指標Ⅱ(APACHE Ⅱ )評分及CT 評分比較差異無顯著性(Pgt; 0.05);早期組急性呼吸窘迫綜合征、腎功能不全的持續時間低于晚期組(Plt; 0.05);早期組和晚期組中轉手術率分別12.5%(3/24例)和 18.18%(2/11例),差異無統計學意義(Pgt; 0.05);病死率早期組和晚期組分別為 8.33%(2/24例)和9.09%(1/11例),差異無統計學意義(Pgt; 0.05);早期組和晚期組住院病程分別為(20.40±18.25)d 和(34.92±12.62)d,兩組比較有統計學意義(Plt; 0.05)。結論:早期使用益活清下法對SAP合并腎功能不全可以取得更好療效。
ObjectiveTo summarize and analyze the etiologies of recurrent acute pancreatitis (RAP) and then conclude the prevention and treatment strategies.MethodSearching relevant literatures of PubMed, CNKI, Wanfang data and other databases in recent years, the etiologies of RAP were analysed and reviewed, then the prevention and treatment strategies were developed.ResultsThe causes of RAP included abnormal function and structure of biliopancreatic duct, metabolic factors, bad living habits, genetic factors and so on. Then based on etiologies of RAP, prevention and treatment strategies of it were summarized.ConclusionsWith the developments of related researches and clinical diagnosis and treatment technologies, the etiologies of RAP are gradually revealed. It is of great significance to clarify the etiologies of RAP and make prevention and treatment strategies for reducing the recurrence of acute pancreatitis.
Objective To evaluate the effectiveness and safety of early veno-venous hemofiltration in patients with severe acute pancreatitis (SAP). Methods We searched Cochrane Central Register of Controlled Trials (Issue 4, 2005), MEDLINE (1990 to 2006) and CBMdisc (1990 to 2006). We also handsearched the references of relevant articles. We included randomized controlled trials (RCTs) and non-randomized clinical controlled trials (CCTs) comparing early veno-venous hemofiltration versus conventional therapy only, which reported either mortality rate, cure rate, or both. Two reviewers assessed the quality of each trial and extracted data independently. Trials were graded methodologically. The Cochrane Collaboration’s RevMan 4.2.8 software was used for statistical analysis. Results Ten RCTs and 6 CCTs involving 891 patients were included, all of which were China-based. The Jadad scores of all included RCTs were less than 3. Five trials were incorrectly described as having used random allocation. The baseline data of each trial were comparable. Meta-analyses showed that hemofiltration significantly increased the overall cure rate (OR 3.01, 95%CI 1.28 to 7.09) and decreased the overall mortality rate (OR 0.43, 95%CI 0.27 to 0.70). Moreover, APACHE-II score, conversion to operation rate and incidence of complications of SAP were reduced significantly., The duration of abdominal pain or distension and hospitalization stay were shortened compared with non-hemofiltration. However, continuous veno-venous hemofiltration (CVVH) did not improve overall prognosis, with greater possibility of adverse events. Repeated or intermittent short veno-venous hemfiltration (RSVVH/ISVVH) either with or without peritoneal dialysis, could improve the overall prognosis without any adverse events reported. Conclusions Based on these findings, early RSVVH/ISVVH was effective and safe for SAP, but the efficacy of CVVH could not be proven. Current studies were only available from China and were poor in methodological quality. Further, high-quality, large-scale, randomized controlled trials are required to identify reliably the effectiveness and safety of early veno-venous hemofiltration for SAP.
【摘要】 目的 觀察利膽清微丸治療慢性膽囊炎濕熱蘊結兼血瘀證患者的療效及安全性，進一步為臨床研究提供依據。 方法 2001年4—7月，采用雙盲、雙模擬、隨機平行對照臨床試驗，將40例患者隨機分為試驗組（20例）及對照組（20例）。試驗組服用利膽清微丸3.5 g/次，3次/d，同時服用膽寧片模擬劑；對照組服用膽寧片3片/次，3次/d，同時服用利膽清微丸模擬劑。 結果 試驗組痊愈1例，顯效12例，有效5例，無效2例，顯效率65%，有效率90%；對照組痊愈2例，顯效10例，有效7例，無效1例，顯效率60%，有效率95%，兩組療效比較差異無統計學意義（Pgt;0.05）。試驗過程中未發現明顯不良反應。 結論 利膽清微丸對于治療慢性膽囊炎濕熱蘊結兼血瘀證有良好效果，是一種安全有效的藥物。【Abstract】 Objective To observe the safety and efficacy of Lidanqing pellet on chronic cholecystitis with damp and hot accumulate knot including blood stasis, and to provide a basis for further clinical trials. Methods A double-blind, double dummy, randomized, and controlled clinic trial was undertaken between April and July 2001. A total of 40 patients were randomly divided into trail group and control group. The trial group was given Lidanqin pellet 3.5 g per time, and three times per day; simultaneously taking Danning tablet simulation agent. The control group was given 3 tablets of Danning tablet per time and three times per day; simultaneously taking taking Lidanqing pellets simulation agent. Results In the trail group, one patient was cured, the therapeutic effect was obvious in 12, basically effective in five and invalid in two (with the rate of obvious effect of 65.00% and rate of basic effect of 90.00%). In the control group, two patients was cured, the therapeutic effect was obvious in 12, basically effective in 10, effective in seven and invalid in one (with the rate of basic effect of 60.00% and the rate of obvious effect of 95.00%). The difference between the two groups was significant (Pgt;0.05). Adverse reaction was not found in the trial group. Conclusion Lidanqing pellet, a safe medication, is effective on chronic cholecystitis with damp and hot accumulate knot including blood stasis.
Objective To assess the effectiveness and safety of Fushenqudu capsules in the treatment of chronic renal failure. Methods The double blind, double dummy and randomized controlled method was adopted. One hundred and thirty one patients were randomized to the trial group (n=88, Fushenqudu capsule, 4 capsules, qid) and the control group (n =43, Shenshuaining capsules, 4 capsules, qid). The therapeutic duration for both groups was 8 weeks. Results The results were analyzed on the basis of intention-to-treat. For effectiveness of treatment, the markedly effective rate was 27.3% (24/88); the total effective rate was 67.0% (59/88) in the treatment group; the markedly effective rate was 25.6% (11/43), the total effective rate was 58.1% (25/43) in the control group. There was no statistical difference between the two groups (Pgt;0.05). For effectiveness of Pishenqixu syndrome, the markedly effective rate was 48.9% (43/88) and 53.3% (23/43) respectively in the trial and control groups. No statistically significant difference was tested between the two groups (Pgt;0.05). Mild adverse effects occurred in two groups. When a smaller dose or termination of the drug were applied, the symptoms went. The tolerance was good when the patients took the medicine regularly. Conclusions Fushenqudu capsules have the same clinical effect as Shenshuaining capsule with a little toxic adverse effects.